Tuesday, 16 June 2015

Enbrel (etanercept) (Rheumatoid Arthritis) Market - Future Growth, Opportunities and Forecast 2023


Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. 

With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.  Amgen's Enbrel (etanercept) is a soluble TNF inhibitor used for the treatment of moderate-to-severe active RA patients who are unresponsive to one or more csDMARDs. Enbrel is a leading biologic agent and is approved for multiple immunological indications, including psoriasis and ankylosing spondylitis. 

Read Complete Report with TOC: http://www.radiantinsights.com/research/enbrel-etanercept-rheumatoid-arthritis-forecast-and-market-analysis-to-2023 

It is a fusion protein made by recombinant DNA technology, where the TNF receptor is combined with the Fc portion of human immunoglobulin G1 (IgG1). Enbrel binds to and neutralizes both lymphotoxin and TNFa, thus preventing synovial inflammation (DrugBank, 2012; Scott, 2012).  


- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on Enbrel (Etanercept) including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for Enbrel (Etanercept) for the top 10 countries from 2013 to 2023. 
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India.  

Reasons To Buy  

- Understand and capitalize by identifying products that are most likely to ensure a robust return. 
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis. 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. 
- Make more informed business decisions from insightful and in-depth analysis of Enbrel (Etanercept) performance. 
- Obtain sales forecast for Enbrel (Etanercept) from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).

About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. 

For More Information Visit – Radiant Insights

Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com

No comments:

Post a Comment